PMID- 38420797
OWN - NLM
STAT- MEDLINE
DCOM- 20240301
LR  - 20240301
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 29
IP  - 2
DP  - 2024 Feb 5
TI  - Polymorphism of HLA and Susceptibility of Breast Cancer.
PG  - 55
LID - 10.31083/j.fbl2902055 [doi]
AB  - Breast cancer (BC) is the second most common malignancy in the world. Numerous 
      studies have demonstrated the association between human leukocyte antigen (HLA) 
      and cancer. The occurrence and development of BC are closely linked to genetic 
      factors. Human leukocyte antigens G and E (HLA-G and HLA-E) are non-classical 
      major histocompatibility complex (MHC) class I molecules. These molecules play an 
      important role in immune surveillance by inhibiting the cytotoxic and natural 
      killer T cells responsible for immune escape. The expression of HLA-G and HLA-E 
      has been associated with several diseases, including tumors. The HLA system plays 
      a key role in the escape of tumor cells from immune surveillance. This review 
      aims to determine the correlation between BC susceptibility and HLA markers 
      specific HLA alleles such as HLA-B07, HLA-DRB111, HLA-DRB113, and HLA-DRB115 are 
      associated with an increased risk of developing BC. Furthermore, HLA-G mutations 
      have been attributed to an elevated likelihood of metastasis in BC patients. 
      Understanding the complex associations between the HLA system and BC development 
      is critical for developing novel cancer prevention, detection, and treatment 
      strategies. This review emphasizes the importance of analyzing HLA polymorphisms 
      in the management of BC patients, as well as the urgent need for further research 
      in this area.
CI  - (c) 2024 The Author(s). Published by IMR Press.
FAU - Aboulaghras, Sara
AU  - Aboulaghras S
AD  - Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V 
      University in Rabat, 10106 Rabat, Morocco.
FAU - Khalid, Asaad
AU  - Khalid A
AD  - Substance Abuse and Toxicology Research Center, Jazan University, 114 Jazan, 
      Saudi Arabia.
AD  - Medicinal and Aromatic Plants Research Institute, National Center for Research, 
      11111 Khartoum, Sudan.
FAU - Makeen, Hafiz A
AU  - Makeen HA
AD  - Pharmacy Practice Research Unit, Clinical Pharmacy Department, Faculty of 
      Pharmacy, Jazan University, 82822 Jazan, Saudi Arabia.
FAU - Alhazmi, Hassan A
AU  - Alhazmi HA
AD  - Substance Abuse and Toxicology Research Center, Jazan University, 114 Jazan, 
      Saudi Arabia.
AD  - Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, 
      Jazan University, 82822, Jazan, Saudi Arabia.
FAU - Albratty, Mohammed
AU  - Albratty M
AD  - Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, 
      Jazan University, 82822, Jazan, Saudi Arabia.
FAU - Mohan, Syam
AU  - Mohan S
AD  - Substance Abuse and Toxicology Research Center, Jazan University, 114 Jazan, 
      Saudi Arabia.
AD  - School of Health Sciences, University of Petroleum and Energy Studies, Dehradun, 
      248001 Uttarakhand, India.
FAU - Goh, Bey Hing
AU  - Goh BH
AD  - Sunway Biofunctional Molecules Discovery Centre, School of Medical and Life 
      Sciences, Sunway University Malaysia, Bandar Sunway, 47500 Selangor Darul Ehsan, 
      Malaysia.
AD  - College of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, 
      Zhejiang, China.
FAU - Yeo, Chien Ing
AU  - Yeo CI
AD  - Sunway Biofunctional Molecules Discovery Centre, School of Medical and Life 
      Sciences, Sunway University Malaysia, Bandar Sunway, 47500 Selangor Darul Ehsan, 
      Malaysia.
FAU - Tan, Yee Seng
AU  - Tan YS
AD  - Sunway Biofunctional Molecules Discovery Centre, School of Medical and Life 
      Sciences, Sunway University Malaysia, Bandar Sunway, 47500 Selangor Darul Ehsan, 
      Malaysia.
FAU - Bouyahya, Abdelhakim
AU  - Bouyahya A
AD  - Laboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V 
      University in Rabat, 10106 Rabat, Morocco.
LA  - eng
GR  - ISP23-81/Deputyship for Research and Innovation, Ministry of Education in Saudi 
      Arabia/
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 0 (HLA-G Antigens)
RN  - 0 (HLA-E Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - Female
MH  - *HLA-G Antigens/genetics
MH  - *Breast Neoplasms/genetics
MH  - HLA-E Antigens
MH  - Polymorphism, Genetic
MH  - Histocompatibility Antigens Class II/genetics
OTO - NOTNLM
OT  - breast cancer
OT  - genetic polymorphism
OT  - prevention
COIS- The authors declare no conflict of interest.
EDAT- 2024/02/29 06:42
MHDA- 2024/03/01 06:44
CRDT- 2024/02/29 05:37
PHST- 2023/05/26 00:00 [received]
PHST- 2023/10/26 00:00 [revised]
PHST- 2023/11/02 00:00 [accepted]
PHST- 2024/03/01 06:44 [medline]
PHST- 2024/02/29 06:42 [pubmed]
PHST- 2024/02/29 05:37 [entrez]
AID - S2768-6701(23)01103-6 [pii]
AID - 10.31083/j.fbl2902055 [doi]
PST - ppublish
SO  - Front Biosci (Landmark Ed). 2024 Feb 5;29(2):55. doi: 10.31083/j.fbl2902055.